|
|||||
|
|
Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS) |
|
| Authors: | Nakase Hiroshi Hayashi Yuki Hirayama Daisuke Matsumoto Takayuki Matsuura Minoru Iijima Hideki Matsuoka Katsuyoshi Ohmiya Naoki Ishihara Shunji Hirai Fumihito Abukawa Daiki Hisamatsu Tadakazu |
| Affiliation: | 1.Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuoku, Sapporo, Hokkaido, 060-8543, Japan ;2.Division of Gastroenterology, Department of Medicine, Iwate Medical University, Morioka, Japan ;3.Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan ;4.Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan ;5.Department of Gastroenterology and Hepatology, Toho University Sakura Medical Center, Chiba, Japan ;6.Department of Gastroenterology, Fujita Health University School of Medicine, Aichi, Japan ;7.Department of Gastroenterology, Faculty of Medicine, Shimane University, Izumo, Japan ;8.Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan ;9.Department of Gastroenterology and Hepatology, Miyagi Children’s Hospital, Sendai, Japan ; |
| Abstract: | Background The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health of people worldwide. The clinical background and clinical course of inflammatory bowel disease (IBD) among Japanese patients with COVID-19 remains unclear. MethodsThis study is an observational cohort of Japanese IBD patients diagnosed with COVID-19. Data on age, sex, IBD (classification, treatment, and activity), COVID-19 symptoms and severity, and treatment of COVID-19 were analyzed. ResultsFrom 72 participating facilities in Japan, 187 patients were registered from June 2020 to October 2021. The estimated incidence of COVID19 in Japanese IBD patients was 0.61%. The majority of IBD patients with COVID-19 (73%) were in clinical remission. According to the WHO classification regarding COVID-19 severity, 93% (172/184) of IBD patients had non-severe episodes, while 7% (12/184) were severe cases including serious conditions. 90.9% (165/187) of IBD patients with COVID-19 had no change in IBD disease activity. A logistic regression analysis stepwise method revealed that older age, higher body mass index (BMI), and steroid use were independent risk factors for COVID-19 severity. Six of nine patients who had COVID-19 after vaccination were receiving anti-tumor necrosis factor (TNF)-α antibodies. ConclusionAge, BMI and steroid use were associated with COVID-19 severity in Japanese IBD patients. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |